Cambridge Investment Research Advisors’s Exelon EXC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.5M Sell
213,252
-8,456
-4% -$393K 0.03% 601
2025
Q4
$9.66M Buy
221,708
+17,283
+8% +$789K 0.03% 599
2025
Q3
$9.2M Buy
204,425
+31,217
+18% +$1.37M 0.03% 598
2025
Q2
$7.52M Buy
173,208
+14,383
+9% +$640K 0.02% 666
2025
Q1
$7.32M Buy
158,825
+9,236
+6% +$386K 0.02% 623
2024
Q4
$5.63M Buy
149,589
+27,230
+22% +$1.06M 0.02% 741
2024
Q3
$4.96M Sell
122,359
-3,484
-3% -$131K 0.02% 799
2024
Q2
$4.36M Buy
125,843
+3,025
+2% +$112K 0.02% 829
2024
Q1
$4.61M Sell
122,818
-18,768
-13% -$671K 0.02% 793
2023
Q4
$5.08M Buy
141,586
+7,215
+5% +$278K 0.02% 698
2023
Q3
$5.08M Buy
134,371
+10,006
+8% +$408K 0.02% 638
2023
Q2
$5.07M Buy
124,365
+9,940
+9% +$411K 0.02% 652
2023
Q1
$4.79M Buy
114,425
+4,726
+4% +$197K 0.02% 650
2022
Q4
$4.74M Sell
109,699
-2,645
-2% -$104K 0.02% 623
2022
Q3
$4.21M Buy
112,344
+1,755
+2% +$77.6K 0.02% 642
2022
Q2
$5.01M Buy
110,589
+2,071
+2% +$97.4K 0.03% 586
2022
Q1
$5.17M Sell
108,518
-24,797
-19% -$1.05M 0.02% 615
2021
Q4
$5.49M Buy
133,315
+3,793
+3% +$143K 0.02% 601
2021
Q3
$4.47M Sell
129,522
-3,118
-2% -$107K 0.02% 658
2021
Q2
$4.19M Sell
132,640
-4,544
-3% -$146K 0.02% 710
2021
Q1
$4.28M Sell
137,184
-520
-0.4% -$15.6K 0.02% 626
2020
Q4
$4.15M Sell
137,704
-25,943
-16% -$766K 0.02% 594
2020
Q3
$4.17M Buy
163,647
+4,718
+3% +$125K 0.03% 524
2020
Q2
$4.11M Buy
158,929
+7,618
+5% +$202K 0.03% 502
2020
Q1
$3.97M Sell
151,311
-18,780
-11% -$591K 0.04% 435
2019
Q4
$5.53M Buy
170,091
+29,560
+21% +$957K 0.04% 427
2019
Q3
$4.84M Sell
140,531
-19,496
-12% -$655K 0.04% 420
2019
Q2
$5.47M Buy
160,027
+6,717
+4% +$237K 0.05% 357
2019
Q1
$5.48M Sell
153,310
-15,810
-9% -$538K 0.05% 343
2018
Q4
$5.44M Sell
169,120
-9,547
-5% -$305K 0.06% 296
2018
Q3
$5.56M Buy
178,667
+17,081
+11% +$526K 0.05% 339
2018
Q2
$4.91M Sell
161,586
-16,729
-9% -$479K 0.05% 337
2018
Q1
$4.96M Buy
178,315
+33,364
+23% +$901K 0.06% 321
2017
Q4
$4.08M Buy
144,951
+8,991
+7% +$258K 0.05% 359
2017
Q3
$3.65M Buy
135,960
+13,687
+11% +$366K 0.05% 337
2017
Q2
$3.15M Sell
122,273
-6,168
-5% -$157K 0.05% 372
2017
Q1
$3.3M Sell
128,441
-26,961
-17% -$687K 0.06% 317
2016
Q4
$3.93M Sell
155,402
-6,936
-4% -$164K 0.07% 253
2016
Q3
$3.85M Buy
162,338
+10,381
+7% +$261K 0.07% 268
2016
Q2
$3.94M Buy
151,957
+35,229
+30% +$871K 0.08% 229
2016
Q1
$2.99M Buy
116,728
+17,022
+17% +$381K 0.07% 278
2015
Q4
$1.98M Sell
99,706
-9,187
-8% -$186K 0.05% 357
2015
Q3
$2.31M Buy
108,893
+19,973
+22% +$449K 0.07% 279
2015
Q2
$1.99M Sell
88,920
-5,760
-6% -$138K 0.06% 313
2015
Q1
$2.27M Sell
94,680
-566
-0.6% -$14K 0.06% 284
2014
Q4
$2.52M Sell
95,246
-15,087
-14% -$387K 0.08% 246
2014
Q3
$2.68M Sell
110,333
-6,292
-5% -$147K 0.08% 249
2014
Q2
$3.04M Buy
116,625
+673
+0.6% +$17.2K 0.11% 186
2014
Q1
$2.78M Buy
115,952
+8,800
+8% +$185K 0.1% 182
2013
Q4
$2.09M Sell
107,152
-3,785
-3% -$76.2K 0.09% 222
2013
Q3
$2.35M Buy
110,937
+7,049
+7% +$154K 0.1% 193
2013
Q2
$2.29M Buy
+103,888
New +$2.52M 0.12% 177

Other funds holding EXC

Cambridge Investment Research Advisors's EXC Position: Q1 2026 in Review

Cambridge Investment Research Advisors reduced its Exelon (EXC) stake by 3.8% in Q1 2026, selling an estimated $393K and leaving 213,252 shares worth $10.5M. The position accounts for 0.03% of the portfolio, ranked #601.

Cambridge Investment Research Advisors first reported a position in EXC in Q2 2013 and has held it in 52 quarters since. 1,277 funds tracked by Wall St. Rank hold EXC as of Q1 2026.

  • Cambridge Investment Research Advisors held 213,252 shares of Exelon worth $10.5M as of Q1 2026.
  • Cambridge Investment Research Advisors sold 8,456 Exelon shares in Q1 2026, an estimated $393K.
  • Exelon made up 0.03% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #601 holding.
  • Cambridge Investment Research Advisors first reported a position in Exelon in Q2 2013 and has held it in 52 quarters since.
  • 1,277 funds tracked by Wall St. Rank held Exelon as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.